Permethrin-treated Baby-wraps for the Prevention of Malaria in Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-03

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The scientific objective of this study is to test the protective effect of permethrin-treated lesus against P. falciparum malaria in infants and young children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Getting Malaria "Off the Back" of Women and Children in Western Uganda

NCT04102592

Malaria

COMPLETED NA

A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda

NCT00118027

Malaria Pregnancy Anemia

COMPLETED NA

Preventing Malaria During Pregnancy in Epidemic-prone Areas.

NCT00142207

Malaria, Falciparum

COMPLETED PHASE3

Effects of Insecticide Treated Bednets on Child Morbidity and Mortality

NCT00225368

Malaria All-cause Mortality

COMPLETED NA

School Based Malaria Control in Ugandan Schoolchildren

NCT01231880

Malaria

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

General Study Design: The proposed study is a double-blind, randomized control trial of permethrin-treated lesus to prevent P. falciparum malaria in children 6-24 months of age conducted at two sites in rural western Uganda. Participating mother-infant pairs will receive a new bed net and two permethrin-treated or untreated lesus at enrollment. The total sample size will be 400 mother-infant pairs with 200 pairs in each group. The investigators will follow participants longitudinally for six months. Participants will be instructed and incentivized to present to one of the two study clinics when a fever develops, where they will be evaluated, tested, and treated, if positive, for malaria. Participants will also attend scheduled clinic visits every two weeks for routine surveillance of adverse effects and to test for asymptomatic infection. Re-treatment and sham re-treatment of lesus will occur each month.

Outcome Measures: The primary outcome measure is the incidence rate ratio of clinical (i.e., symptomatic) P. falciparum malaria in infants and children 6 - 24 months of age. Differences in malaria infection between treatment groups will be estimated with the incidence rate ratio, defined as the ratio of the number of clinical malaria episodes per 100 person-weeks at risk in the intervention group relative to the control group. This measure was chosen as it represents the most patient-centered measure of malaria burden, reflecting not only the potential negative health consequences, but also opportunity costs associated with care seeking and treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria P. Falciparum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a double-blind, randomized controlled trial of permethrin-treated lesus to prevent P. falciparum malaria in children 6-18 months of age. Study enrollment conducted at two sites in rural western Uganda. Participants will be randomized to one of two arms: permethrin-treated (intervention) or untreated (control) lesus. Participating mother-infant pairs will receive a new Long-lasting Insecticidal Net and two permethrin-treated or untreated lesus at enrollment. Total sample size will be 400 mother-infant pairs with 200 pairs in each arm. Participants will be followed longitudinally for six months, instructed and incentivized to present to one of the two study clinics when a fever develops, where they will be evaluated, tested, and treated, if positive, for malaria. Participants will attend scheduled clinic visits every two weeks for routine surveillance of adverse effects and tested for asymptomatic infection. Re-treatment and sham re-treatment of lesus will occur monthly.

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Double

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Arm : Arm that received permethrin-treated lesu

Intervention Arm is the group that receives permethrin-treated lesu for use. The lesus of participants in the intervention group will be treated and subsequently retreated each month with 0.5% permethrin (Sawyer Products, Safety Harbor, FL).

Group Type EXPERIMENTAL

Permethrin-treated lesu

Intervention Type OTHER

0.5% permethrin soaked baby wraps (lesus)

Control Arm: Arm that received none permethrin-treated lesu

The lesus of participants in the control group will undergo sham treatment and re-treatment in which the cloth is soaked in water for a period of time similar to that of the intervention group. Participants and clinical staff (but not administrative staff) will be blinded to group assignments.

Group Type SHAM_COMPARATOR

Untreated lesu

Intervention Type OTHER

Water soaked baby wraps (lesus)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Permethrin-treated lesu

0.5% permethrin soaked baby wraps (lesus)

Intervention Type OTHER

Untreated lesu

Water soaked baby wraps (lesus)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide signed and dated informed consent form (ICF)
* Willing to comply with all study procedures and be available for the duration of the study
* Female of any age with a child 6 to 18 months of age at the time of enrollment
* Resident of village located in Bugoye, Maliba, or Mubuku sub-counties. Recruitment will initially focus on residents of villages within 2 km of study clinics in order to facilitate attendance, but we will not restrict enrollment to residents of these villages.

Exclusion Criteria

* Mother or child taking any malaria chemoprevention regimen, including individuals living with HIV or exposed children who are taking cotrimoxazole that may modify risk of malaria
* Child with known sickle cell disease
* Known allergic reactions to components of the study product(s)
* Treatment with another investigational drug or other intervention
* Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.

Minimum Eligible Age

6 Months

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes